Epilepsy Neurostimulation as a Treatment Option for Epilepsy Paul Boon1 and Kristl Vonck2 1. Professor of Neurology; 2. Associate Professor of Neurology, Reference Centre for Refractory Epilepsy, Department of Neurology, Ghent University Hospital
Abstract
Although neurostimulation is not a new treatment modality, it is an emerging treatment for various neurological diseases. Currently available pharmacological and surgical treatments leave about 30% of patients not seizure-free. Electrical stimulation of the 10th cranial nerve or vagus nerve stimulation (VNS) is an extracranial type of stimulation that is currently routinely available. Through an implanted device and electrode, electrical pulses are administered to the afferent fibres of the left vagus nerve in the neck. VNS is indicated in patients with refractory epilepsy who are unsuitable candidates for epilepsy surgery or who have had insufficient benefit from such a treatment. Intracerebral neurostimulation requires accessing the intracranial nervous system as stimulation electrodes are inserted into intracerebral targets for deep brain stimulation (DBS) or placed over the cortical convexity for cortical stimulation (CS). Recently, trials with DBS in different intracerebral structures such as the thalamus, the subthalamic nucleus and medial temporal lobe structures have been performed. CS ± DBS in a closed-loop system (responsive neurostimulator system [RNS]) is currently being investigated in a multicentre trial. It is likely that neurostimulation for epilepsy will become a more practical and more widely used treatment modality for patients with refractory epilepsy.
Keywords Neurostimulation, seizures, refractory epilepsy, therapeutic stimulation
Disclosure: Paul Boon and Kristl Vonck are supported by grants from the Ghent University Research Fund (BOF), the Fund for Scientific Research Flanders and the Clinical Epilepsy Research Grant of Ghent University Hospital. Both authors have received speaker and consultancy fees and travel grants from Cyberonics. Paul Boon has received speaker and consultancy fees and free devices for deep brain stimulation studies from Medtronic. Received: 6 June 2010 Accepted: 29 June 2010 Citation: European Neurological Review, 2010;5(1):92–6 Correspondence: Paul Boon, Department of Neurology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. E:
Paul.Boon@UGent.be
Vagus Nerve Stimulation
Electrical stimulation of the 10th cranial nerve or vagus nerve stimulation (VNS) has become a valuable option in the therapeutic armamentarium of adults and children with refractory epilepsy. Since its introduction in 1989 over 50,000 patients have been treated with VNS worldwide. Efficacy, side effects and tolerability have been extensively studied. The precise mechanism of action remains to be elucidated, but some essential intracerebral pathways have been identified.1
Clinical Efficacy
In the early 1990s, initial results from two single-blinded pilot clinical trials (phase I trials EO1 and EO2) in a small group of patients with refractory complex partial seizures from three epilepsy centres in the US were reported.2–5
leading to the EO5 study of 198 patients in the US. Ninety-four patients in the treatment group had a 28% decrease in seizure frequency versus 15% of patients in the control group.11
The controlled EO3 and EO5 studies had their primary efficacy end-point after 12 weeks of VNS. Increased efficacy with longer treatment was found in all published reports on long-term results.12–16
The mean
reduction in seizure frequency increased up to 35% at one year and up to 44% at two years of follow-up. After that, improved seizure control reached a plateau.
In nine out of 14 patients treated for three to 22 months, a reduction in seizure frequency of at least 50% was observed.6 Complex partial seizures, simple partial seizures and secondary generalised seizures were affected. It was noticed that reduction in the frequency, duration and intensity of seizures lagged four to eight weeks after the initiation of treatment.2
In the meantime, two prospective
multicentre (n=17) double-blind randomised studies (EO3 and EO5) were started including patients from centres in the US (n=12), Canada (n=1) and Europe (n=4).7–11
The results of EO3 in 113 patients showed a 24% decrease in seizures in the treatment group versus 6% in the control group after three months of treatment. The number of patients was insufficient to achieve US Food and Drug Administration (FDA) approval,
92
In the following years, other large prospective clinical trials were conducted in different epilepsy centres worldwide. In Sweden, long- term follow-up in the largest patient series (n=67) in one centre not belonging to the sponsored clinical trials at that time reported similar efficacy rates, with a mean decrease in seizure frequency of 44% in patients treated up to five years.17
A joint study of two epilepsy centres
in Belgium and the US included 118 patients with a minimum follow-up duration of six months. They found a mean reduction in monthly seizure frequency of 55%.18
point of view, prospective randomised trials investigating long-term efficacy in comparison with other therapeutic options for patients with refractory epilepsy are still lacking.
© TOUCH BRIEFINGS 2010
Long-term seizure freedom was achieved in only a small minority of patients (7%). In China, a mean seizure reduction of 40% was found in 13 patients after 18 months of VNS.19
From a clinical
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116